VANCOUVER, British Columbia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- LeanLife Health Inc. (the “Company”, or
“LeanLife”) (CSE: LLP) is pleased to provide an update of its processing and manufacturing.
Manufacturing equipment and processing:
The main equipment has been purchased and delivered to the new facility building in Canada comprised of some
4,000 square feet. The Company is awaiting the approval of permits to operate. Total expenditures for manufacturing and lab
equipment including associated costs is some $700,000. Permitting for the manufacturing facility has conditions and requirements
from municipal and provincial levels. The Company has engaged consultants to assist in this process.
Under previous arrangements, product was available in Europe, that the Company mainly used for sample purposes.
Manufacturing was by way of a batch system, considered to be expensive, problematic, and outdated. The Company has acquired a
continuous process manufacturing system bringing efficiency, computer monitoring and control with remote consultancy quality
readout. Moreover, the main manufacturing unit is scalable, with features of additional units added vertically and/or adjacently.
In this way additional production can be added in the same location or new locations in Canada or other countries in a very
efficient manner. It is also possible to have a dedicated line for a single customer enabling customer features or monitoring.
Licensing and permitting:
The Company has begun the process of obtaining federal government certifications in Canada and the United
States. The Company has engaged a consulting firm that specializes in this area, having offices in the US and Canada. Announcements
will be made at an appropriate time. This will be an ongoing process. There are many endorsements and approvals that the Company
desires to obtain. The Company has various approvals at present, but it is not prudent to reveal all at this point.
Planning:
As soon as permitting is complete the Company will begin process production. The Company has initial orders to
fill, and inventory levels must be maintained to ensure that future order levels can also be filled.
Once production starts, the Company’s plan is to develop other location sites.
About LeanLife Health and the Omega 3 Market
LeanLife Health’s products are extracted from flax seeds, a plentiful and non-animal source of Omega 3. The
products can be used as a food additive or as a nutraceutical and can be incorporated in foods such as bread, noodles, cheese,
yogurt, juice and milk products. LeanLife Health’s industry leading Omega 3 product formulations are of the highest quality and
contain no cholesterol. Products will be available in oil, emulsion and powder forms.
The global omega 3 market is expected to reach USD 7.32 billion by 2020, according to a report by Grand
View Research, Inc.
For more information, please contact:
Stan Lis, CEO
Tel: 604 764-0518
E-mail: slis@leanlifehealth.com
Forward Looking Information
Information set forth in this news release contains forward-looking statements that are based on assumptions as
of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations.
They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain
and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control
including, the Company's ability to compete with large food companies; sales of any potential products developed will be
profitable; the ability to complete sales under the sales agreement. Accordingly, actual and future events, conditions and results
may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking
information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or
revise forward-looking information.
THE CSE HAS NEITHER APPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE
